Obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the new medications.

A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...